IntelliCell BioSciences (SVFC.PK) has added new members to its executive management group, too few – too late??
Mr. Robert J. Sexauer has joined as its Executive Vice President. Mr. Sexauer, a 30 year medical technology and regenerative medicine specialist, will concentrate on planned clinical studies as well as corporate development functions. Mr. Sexauer noted, “I am very pleased to be part of a talented management team focused on autologous (your own) cellular therapies. IntelliCell has the remarkable potential to be a leader in the field of regenerative medicine.”
SVFC.PK has also announced that Sarah R. Young has joined as Director of Quality Assurance. Ms. Young has over 10 years of experience developing and implementing quality systems pertaining to the field of tissue processing and tissue banking. Ms. Young stated, “The IntelliCell process for developing cell therapy solutions is very exciting and our group will focus on implementing the highest quality standards for the industry and all of our stakeholders.”
The Bottom Line: They will … need a lot more than these few … to obviate the past … indiscretions and more … how about a regulatory ombudsman and the stock is up … $0.10 <+10%> to $1.10!!







